Optimising Care For Patients With High-Risk AML – BSH Symposia 2021

Dr Amit Patel chairs the panel alongside Prof. Thomas Cluzeau and Dr Sree Munisamy. In the Symposium, Dr Patel will define high-risk AML, while providing a background to the breakthrough trials of Vyxeos Liposomal. Prof. Cluzeau presents the case study of a 69-year-old French woman, in addition to describing the real-world evidence of Vyxeos Liposomal in French and Italian centres. Finally, Dr Munisamy will review the Q-TWiST (QoL) study in the context of the case study of a 69-year-old British woman who contracted COVID-19 during the course of her treatment.

Prescribing Information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Cytogenetics Quality of Life Real-world Data Safety Vyxeos Liposomal Data


Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

UK-VYX-2100137 | July 2021